NCT05867589View on ClinicalTrials.gov

Study of Novel PET Tracer Gallium [68Ga]/ Fluorine [18F] -FAPI-04 in the Diagnosis of Cardiovascular Diseases

NARecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Myocardial Fibrosis

Interventions

DRUG

68Ga/18F-FAPI-04

Subjects will receive one injection of 68Ga/18F-FAPI-04 (0.1\~0.15mCi/Kg), a PET radiopharmaceutical selective for fibroblast activation protein. 68Ga/18F-FAPI-04 injection will be followed by a 10 ml saline flush.

Trial Locations (1)

210006

RECRUITING

Nanjing First Hospital, Nanjing

All Listed Sponsors

lead

Nanjing First Hospital, Nanjing Medical University

OTHER